EFFICACY AND SAFETY OF FIXED COMBINATION THERAPY OF VILDAGLIPTIN AND METFORMIN (25/1000 MG BID) IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH PRIOR METFORMIN MONOTHERAPY (HBA1C 7.0-9.5%):